https://www.selleckchem.com/pr....oducts/fingolimod.ht
© 2020 Scandinavian Psychological Associations and John Wiley Sons Ltd.BACKGROUND AND OBJECTIVE When patients seek to discontinue buprenorphine (BUP) treatment, monthly injectable extended-release naltrexone (XR-NTX) may help them avoid relapse. The efficacy of low ascending doses of oral NTX vs placebo for patients transitioning from BUP to XR-NTX is evaluated in this study. METHODS In a phase 3, hybrid residential/outpatient study, clinically stable participants with opioid use disorder (N = 101), receiving BUP for more than
Like
Comment
Share
